Dendritic cell-based vaccines: Clinical applications in breast cancer

Immunotherapy

Volumn 6, Issue 3, 2014, Pages 349-360

  Gelao, Lucia ^a   Criscitiello, Carmen ^a   Esposito, Angela ^a   Laurentiis, Michele De ^b   Fumagalli, Luca ^a   Locatelli, Marzia Adelia ^a   Minchella, Ida ^a   Santangelo, Michele ^c   Placido, Sabino De ^c   Goldhirsch, Aron ^a   Curigliano, Giuseppe ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

breast cancer; dendritic cells; immune response; immunotherapies; vaccines

Indexed keywords

CD40 LIGAND; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; IPILIMUMAB; CANCER VACCINE; CYTOKINE; PROSTAGLANDIN; TUMOR ANTIGEN;

BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CLINICAL STUDY; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; MEMORY T LYMPHOCYTE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; VACCINATION; ACTIVE IMMUNIZATION; ANIMAL; ANTIGEN PRESENTATION; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DRUG SCREENING; FEMALE; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOSURVEILLANCE; MOUSE; OVARIAN NEOPLASMS; PHYSIOLOGY; PROTO ONCOGENE; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE; TRANSPLANTATION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, TRANSGENIC; OVARIAN NEOPLASMS; PROSTAGLANDINS; T-LYMPHOCYTE SUBSETS; TUMOR ESCAPE; VACCINATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899520319     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.169     Document Type: Review

References (73)

1. Adam JK, Odhav B, Bhoola KD. Immune responses in cancer. Pharmacol. Ther. 99(1), 113-132 (2003).
2. Andre F, Dieci MV, Dubsky P et al. Molecular pathways: Involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin. Cancer Res. 19(1), 28-33 (2013).
3. Yaguchi T, Sumimoto H, Kudo-Saito C. The mechanisms of cancer immunoescape and development of overcoming strategies. Int. J. Hematol. 93(3), 294-300 (2011).
4. Zheng J, Liu Q, Yang J et al. Co-culture of apoptotic breast cancer cells with immature dendritic cells: A novel approach for DC-based vaccination in breast cancer. Braz. J. Med. Biol. Res. 45(6), 510-515 (2012).
5. Penn I. Tumors of the immunocompromised patient. Annu. Rev. Med. 39, 63-73 (1998).
6. Chen Q, Zhang XH, Massague J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 20(4), 538-549 (2011).
7. DeNardo DG, Barreto JB, Andreu P et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16(2), 91-102 (2009).
8. Bidwell BN, Slaney CY, Withana NP et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18(8), 1224-1231 (2012).
9. Mittendorf EA, Peoples GE, Singletary SE Breast cancer vaccines: Promise for the future or pipe dream? Cancer 110(8), 1677-1686 (2007).
10. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
11. Eggermont AM, Kroemer G, Zitvogel L. Immunotherapy and the concept of a clinical cure. Eur. J. Cancer 49(14), 2965-2967 (2013).
12. Palucka K, Banchereau J. Human dendritic cell subsets in vaccination. Curr. Opin. Immunol. 25(3), 396-402 (2013).
13. Criscitiello C, Curigliano G. Immunotherapeutics for breast cancer. Curr. Opin. Oncol. 25(6), 602-608 (2013).
14. Dunn GP, Bruce AT, Ikeda H et al. Cancer immunoediting: From immunosurveillance to tumour escape. Nat. Immunol. 3(11), 991-998 (2002).
15. Curigliano G. Immunity and autoimmunity: Revising the concepts of response to breast cancer. Breast 20(3), 71-74 (2011).
16. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 411(6835), 380-384 (2001).
17. Turnis ME, Rooney CM. Enhancement of dendritic cells as vaccines for cancer. Immunotherapy 2(6), 847-862 (2010).
18. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685-711(2003).
19. Berzofsky JA, Terabe M, Oh S et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113(11), 1515-1525 (2004).
20. Nencioni A, Grünebach F, Schmidt SM et al. The use of dendritic cells in cancer immunotherapy. Crit. Rev. Oncol. Hematol. 65(3), 191-199 (2008).
21. Ma Y, Shurin GV, Peiyuan Z et al. Dendritic cells in the cancer microenvironment. J. Cancer 4(1), 36-44 (2013).
22. Engelhardt JJ, Boldajipour B, Beemiller P et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21(3), 402-417 (2012).
23. Mu CY, Huang JA, Chen Y et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med. Oncol. 28 (3), 682-688 (2011).
24. Eisenbarth SC, Williams A, Colegio OR et al. NLRP10 is a NOD-like receptor essential to initiate adaptive immunity by dendritic cells. Nature 484(7395), 510-513 (2012).
25. Satthaporn S, Robins A, Vassanasiri W et al. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol. Immunother. 53(6), 510-518 (2004)
26. Banchereau J, Schuler-Thurner B, Palucka AK et al. Dendritic cells as vectors for therapy. Cell 106(3), 271-274 (2001).
27. Lee AW, Truong T, Bickham K et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: Implications for immunotherapy. Vaccine 20 (4), 8-22 (2002).
28. Ballestrero A, Boy D, Moran E et al. Immunotherapy with dendritic cells for cancer. Adv. Drug Deliv. Rev. 60(2), 173-183 (2008).
29. Gogas H, Polyzos A, Kirkwood J. Immunotherapy for advanced melanoma: Fulfilling the promise. Cancer Treat Rev. 39(8), 879-885 (2013).
30. Khattak M, Fisher R, Turajlic S et al. Targeted therapy and immunotherapy in advanced melanoma: An evolving paradigm. Ther. Adv. Med. Oncol. 5(2), 105-118 (2013).
31. Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann. Oncol. 23(8), 35-40 (2012).
32. Rini BI, Stein M, Shannon P et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 117, 758-767 (2011).
33. Pal SK, Hu A, Figlin RA. A new age for vaccine therapy in renal cell carcinoma. Cancer J. 19(4), 365-370 (2013).
34. Cheever MA. PROVENGE (sipuleucel-T) in prostate cancer: The first FDA-Approved therapeutic cancer vaccine. Clin. Cancer Res. 17, 3520-3526 (2011).
35. Lissoni P, Vigore L, Ferranti R et al. Circulating dendritic cells in early and advanced cancer patients: Diminished percent in the metastatic disease. J. Biol. Regul. Homeost. Agents 13(4), 216-219 (1999).
36. Fields RC, Shimizu K, Mulé JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl Acad. Sci. USA 95(16), 9482-9487 (1998).
37. Wright SE. Immunotherapy of breast cancer. Expert Opin. Biol. Ther. 12, 479-490 (2012).
38. Gong J, Avigan D, Chen D et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human DCs and breast carcinoma cells. Proc. Natl Acad. Sci. USA 97(6), 2715-2718 (2000).
39. Neidhardt-berard EM, Berard F, Banchereau J et al. Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes. Breast Cancer Res. 6(4), 322-328 (2004).
40. Wang B, Zaidi N, He LZ et al. Targeting of the nonmutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res. 14, R39 (2012).
41. Wang L, Xie Y, Ahmed KA et al. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice. Breast Cancer Res. Treat. 140(2), 273-284 (2013).
42. Sakai Y, Morrison BJ, Burke JD et al. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res. 64(21), 8022-8028 (2004).
43. Huang X, Ye D, Thorpe PE. Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine. Vaccine 29(29-30), 4785-4793 (2011).
44. Brossart P, Wirths S, Stuhler G et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96(9), 3102-2108 (2000).
45. Avigan D, Vasir B, Gong J et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 10(14), 4699-4708 (2004).
46. Qi CJ, Ning YL, Han YS et al. Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer. Cancer Immunol. Immunother. 61(9), 1415-1424 (2012).
47. Baek S, Kim CS, Kim SB et al. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: Results from a Phase I/II trial. J. Transl. Med. 20, 9-178 (2011).
48. ClinicalTrials.gov home page. www.clinicaltrials.gov
49. Cui Y, Yang X, Zhu W et al. Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients. Oncol. Lett. 6(2), 537-541 (2013).
50. Ren J, Di L, Song G et al. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: Reargument of such contentious therapeutic preferences. Clin. Transl. Oncol. 15(10), 780-788. (2013).
51. Finn OJ, Forni G. Prophylactic cancer vaccines. Curr. Opin. Immunol. 14(2), 172-177 (2002).
52. Koski GK, Koldovsky U, Xu S et al. A novel dendritic cellbased immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J. Immunother. 35(1), 54-65 (2012).
53. Czerniecki BJ, Koski GK, Koldovsky U et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 67(4), 1842-1852 (2007).
54. Sharma A, Koldovsky U, Xu S et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 118(17), 4354-4362 (2012).
55. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
56. Galluzzi L, Senovilla L, Vacchelli E et al. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 1(7), 1111-1134 (2012).
57. Strasser EF, Eckstein R. Optimization of leukocyte collection and monocyte isolation for dendritic cell culture. Transfus. Med. Rev. 24(2), 130-139 (2010).
58. Dikov MM, Ohm JE, Ray N. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol. 174, 215-222 (2005).
59. Kawakami Y, Yaguchi T, Sumimoto H et al. Improvement of cancer immunotherapy by combining molecular targeted therapy. Front. Oncol. 3, 136 (2013).
60. Tacken PJ, de Vries IJ, Torensma R et al. Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7, 790-802 (2007).
61. Sancho D, Mourão-Sá D, Joffre OP et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-Type lectin. J. Clin. Invest. 118, 2098-2110 (2008).
62. Bonifaz L, Bonnyay D, Mahnke K et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196, 1627-1638 (2002).
63. Hawiger D, Inaba K, Dorsett Y et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769-779 (2001).
64. Mellor AL, Munn DH. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4 (10), 762-774 (2004).
65. Zheng X, Koropatnick J, Chen D et al. Silencing IDO in dendritic cells: A novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int. J. Cancer 132(4), 967-977 (2013).
66. Criscitiello C. Tumor-Associated antigens in breast cancer. Breast Care (Basel) 7(4), 262-266 (2012).
67. Van Tendeloo VF, Ponsaerts P, Berneman ZN. mRNA based gene transfer as a tool for gene and cell therapy. Curr. Opin. Mol. Ther. 9, 423-431 (2007).
68. Zhang B, Beeghly-Fadiel A, Long J, Genetic variants associated with breast-cancer risk: Comprehensive research synopsis, meta-Analysis, and epidemiological evidence. Lancet Oncol. 12(5), 477-488 (2011).
69. Vonderheide RH, LoRusso PM, Khalil M. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-Associated modulation of inducible costimulator expression on patient T cells. Clin. Cancer Res. 16(13), 3485-3494 (2010).
70. Hodi FS, Butler M, Oble DA. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyteassociated antigen 4 in previously vaccinated cancer patients. Proc. Natl Acad. Sci. USA 105(8), 3005 (2008).
71. Zitvogel L, Apetoh L, Ghiringhelli, F et al. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59-73 (2008).
72. Ghiringhelli F, Apetoh L, Tesniere A et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta dependent adaptive immunity against tumors. Nat. Med. 15, 1170-1178 (2009).
73. Stagg J, Andre F, Loi S Immunomodulation via chemotherapy and targeted therapy: A new paradigm in breast cancer therapy? Breast Care (Basel) 7(4), 267-272 (2012).